Last reviewed · How we verify

Sacubitril / Valsartan Oral Tablet [Entresto]

University Hospital, Grenoble · Phase 3 active Small molecule

Sacubitril / Valsartan Oral Tablet [Entresto] is a ACE2 activator and angiotensin II receptor antagonist Small molecule drug developed by University Hospital, Grenoble. It is currently in Phase 3 development for Chronic heart failure. Also known as: ARNI, LCZ696 100 mg tablet, Angiotensin receptor-neprilisin inhibitor (ARNI), LCZ696.

Sacubitril is an angiotensin-converting enzyme 2 (ACE2) activator, while valsartan is an angiotensin II receptor antagonist.

Sacubitril is an angiotensin-converting enzyme 2 (ACE2) activator, while valsartan is an angiotensin II receptor antagonist. Used for Chronic heart failure.

At a glance

Generic nameSacubitril / Valsartan Oral Tablet [Entresto]
Also known asARNI, LCZ696 100 mg tablet, Angiotensin receptor-neprilisin inhibitor (ARNI), LCZ696
SponsorUniversity Hospital, Grenoble
Drug classACE2 activator and angiotensin II receptor antagonist
TargetACE2 and AT1R
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Sacubitril works by increasing the levels of a naturally occurring enzyme called ACE2, which breaks down angiotensin II. Valsartan blocks the action of angiotensin II, a potent vasoconstrictor, by binding to its receptor. This dual mechanism of action leads to vasodilation and decreased blood pressure.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sacubitril / Valsartan Oral Tablet [Entresto]

What is Sacubitril / Valsartan Oral Tablet [Entresto]?

Sacubitril / Valsartan Oral Tablet [Entresto] is a ACE2 activator and angiotensin II receptor antagonist drug developed by University Hospital, Grenoble, indicated for Chronic heart failure.

How does Sacubitril / Valsartan Oral Tablet [Entresto] work?

Sacubitril is an angiotensin-converting enzyme 2 (ACE2) activator, while valsartan is an angiotensin II receptor antagonist.

What is Sacubitril / Valsartan Oral Tablet [Entresto] used for?

Sacubitril / Valsartan Oral Tablet [Entresto] is indicated for Chronic heart failure.

Who makes Sacubitril / Valsartan Oral Tablet [Entresto]?

Sacubitril / Valsartan Oral Tablet [Entresto] is developed by University Hospital, Grenoble (see full University Hospital, Grenoble pipeline at /company/university-hospital-grenoble).

Is Sacubitril / Valsartan Oral Tablet [Entresto] also known as anything else?

Sacubitril / Valsartan Oral Tablet [Entresto] is also known as ARNI, LCZ696 100 mg tablet, Angiotensin receptor-neprilisin inhibitor (ARNI), LCZ696.

What drug class is Sacubitril / Valsartan Oral Tablet [Entresto] in?

Sacubitril / Valsartan Oral Tablet [Entresto] belongs to the ACE2 activator and angiotensin II receptor antagonist class. See all ACE2 activator and angiotensin II receptor antagonist drugs at /class/ace2-activator-and-angiotensin-ii-receptor-antagonist.

What development phase is Sacubitril / Valsartan Oral Tablet [Entresto] in?

Sacubitril / Valsartan Oral Tablet [Entresto] is in Phase 3.

What are the side effects of Sacubitril / Valsartan Oral Tablet [Entresto]?

Common side effects of Sacubitril / Valsartan Oral Tablet [Entresto] include hypotension, dizziness, cough.

What does Sacubitril / Valsartan Oral Tablet [Entresto] target?

Sacubitril / Valsartan Oral Tablet [Entresto] targets ACE2 and AT1R and is a ACE2 activator and angiotensin II receptor antagonist.

Related